Novandi Chemistry AB
Johan Sandell is the CEO of Novandi Chemistry AB since January 2013. Prior to this role, Johan held positions as Associate Director/Team leader at AstraZeneca R&D and Senior Scientist at various companies. Johan has a diverse educational background, with degrees in Chemical Engineering, Experimental Neuroscience, and Positron Emission Tomography. Johan specializes in the synthesis and labeling of drug candidates and radioligands for imaging purposes.
This person is not in any teams
Novandi Chemistry AB
Novandi Chemistry's mission is to deliver isotope labeling of substances, chemistry support for nuclear medicine applications, consulting services and R&D in isotope and radiopharmaceutical chemistry. The company offers a comprehensive carbon-14, tritium and stable labeling service and acts as a hub for non-regulatory and regulatory compliant studies with radiolabeled compounds and drug candidates. The company offers a long-term responsibility for radioactive labeled substances through storage, continuous quality control and repurification. Thus, the company can guarantee high quality compounds and simplify the logistics of studies with radiolabeled compounds. The company also offers a general chemistry support for nuclear medicine applications such as positron emission tomography, and consulting service in isotope chemistry, radiation safety (beta radiation), radioligand development and radiopharmaceutical chemistry.